Screener
ImmunityBio, Inc. IBRX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Reconciliation of cash, cash equivalents, and restricted cash, end of period: | ||
| Cash and cash equivalents | $205,194 | $60,660 |
| Restricted cash (included in Other Assets) | 1,276 | 484 |
| Cash, cash equivalents, and restricted cash, end of period | $206,470 | $61,144 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid during the period for: | ||
| Interest | $20,115 | $15,593 |
| Non-cash investing and financing activities: |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s restricted cash?
- ImmunityBio, Inc. (IBRX) reported restricted cash of $1.28M in Q1 2026.
- How has ImmunityBio, Inc.'s restricted cash changed year-over-year?
- ImmunityBio, Inc.'s restricted cash increased by 163.6% year-over-year, from $484K to $1.28M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about ImmunityBio, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude